Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

Houston, Texas and Tuebingen, Germany, July 17, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced three presentations at the European Society for Medical Oncology (ESMO) Congress 2026, to be held from October 23-27, 2026, in Madrid, Spain.